Angela T.H. Kwan, MD(C), MSc

The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.

Measures of cognitive function and depressive symptoms improved to a greater extent with vortioxetine than with escitalopram or sertraline in post-COVID syndrome participants with MDD.